Sfoglia per Autore "Mandala, E."
Items 1-8 di 8
-
Influence of common thrombophilia polymorphisms on the thrombosis risk in patients with JAK2-V617F-positive myeloproliferative neoplasms
Giamouris, V.; Befani, M.; Papadakis, E.; Mandala, E.; Papadoulis, N.; Karamagiolis, S.; Gastari, V.; Verrou, E.; Katodritou, E.; Lafioniatis, S.; Kartasis, Z.; Magiannis, K.; Marinaki, P.; Tsioni, K.; Kioumi, A.; Germenis, A. E.; Speletas, M. (2012) -
Methylation status of RASSF1A in patients with chronic myeloid leukemia
Avramouli, A.; Tsochas, S.; Mandala, E.; Katodritou, E.; Ioannou, M.; Ritis, K.; Speletas, M. (2009)RASSF1A, a key cell cycle related gene, is expressed in all hematopoietic cells, it is implicated in ras signaling pathway and its promoter hypermethylation is observed in a wide variety of solid tumors. Till now, RASSF1A ... -
Prevalence of thrombophilia genes in patients with idiopathic thromboembolic disease
Mandala, E.; Lafaras, C.; Dardavesis, T.; Speletas, M.; Platogiannis, D.; Tsioni, C.; Douvleti, E.; Ilonidis, G. (2007) -
Prevalence of thrombophilic mutations in patients with unprovoked thromboembolic disease. A comparative analysis regarding arterial and venous disease
Mandala, E.; Lafaras, C.; Tsioni, C.; Speletas, M.; Papageorgiou, A.; Kleta, D.; Dardavessis, T.; Ilonidis, G. (2012)Background: Thromboembolic disease (TED) represents one of the main reasons of morbitity and mortality in Western World. Venous and arterial thrombotic disorders have long been viewed as separate pathophysiological entities. ... -
Survivin isoform expression patterns in CML patients correlate with resistance to imatinib and progression, but do not trigger cytolytic responses
Speletas, M.; Argentou, N.; Karanikas, V.; Gramoustianou, E. S.; Mandala, E.; Braimi, M.; Matsouka, P.; Ritis, K.; Germenis, A. E. (2011)Tyrosine-kinase inhibitors are very effective in patients with CML, but in most cases the disease relapses after their discontinuation. As a result, novel approaches should be considered, such as anti-survivin treatment ... -
TACI Expression and Signaling in Chronic Lymphocytic Leukemia
Mamara, A.; Germenis, A. E.; Kompoti, M.; Palassopoulou, M.; Mandala, E.; Banti, A.; Giannakoulas, N.; Speletas, M. (2015)TACI is a membrane receptor of BAFF and APRIL, contributing to the differentiation and survival of normal B cells. Although malignant B cells are also subjected on TACI signaling, there is a remarkable intradisease and ... -
TLR4 single nucleotide polymorphisms and thrombosis risk in patients with myeloproliferative disorders
Speletas, M.; Liadaki, K.; Kalala, F.; Daiou, C.; Katodritou, E.; Mandala, E.; Korantzis, I.; Ritis, K.; Zintzaras, E.; Germenis, A. E. (2008) -
TNFRSF13B/TACI and TNFRSF13C/BAFFR in B cell chronic lymphocytic leukemia (B-CLL)
Mamara, A.; Kalala, F.; Florou, Z.; Mandala, E.; Palasopoulou, M.; Mpardaka, F.; Giannakoulas, N.; Mpanti, A.; Germenis, A. E.; Speletas, M. (2012)